Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03575104 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

A Phase 3 study, sponsored by Idorsia Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
924
Enrollment target

NCT03575104: Completed Phase 3 study, sponsored by Idorsia Pharmaceuticals.

NCT03575104 is a Phase 3 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 924 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03575104, a Phase 3 study, has completed, sponsored by Idorsia Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
924 participants
Enrollment target

Study Summary

The main purpose of this study is to assess efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

Primary Outcome

"Wake After Sleep Onset" is the time spent awake after onset of persistent sleep until lights on, as determined by polysomnography.

Interventions

  • OTHER Placebo
  • DRUG Daridorexant

Trial Details

FieldValue
Enrollment Target 924 participants
Start Date 2018-05-29
Est. Completion 2020-05-14
Phase Phase 3
Idorsia Pharmaceuticals

34 total trials

What the finished NCT03575104 record still lists

NCT03575104 is an interventional study that assigns participants to a tested intervention. The registered 924 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03575104 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03575104 about?

NCT03575104 is a clinical study titled "Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep". The main purpose of this study is to assess efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

What is the current status of trial NCT03575104?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 924 participants. The study started on 2018-05-29. Estimated completion is 2020-05-14.

What interventions are being tested in trial NCT03575104?

The interventions under investigation include: Placebo (OTHER), Daridorexant (DRUG).

Who is sponsoring clinical trial NCT03575104?

This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03575104's enrollment target sits among peer trials

924 342nd of 2000 higher than 1,658 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04692493 · 924 participants · Phase 3

    Ra-pro Pragmatic Trial

  • NCT05656807 · 924 participants · NA

    Evaluation of Child Care Staff Weight Management Program

  • NCT06082453 · 924 participants · NA

    Modernizing Perinatal Syphilis Testing

  • NCT03995082 · 925 participants · NA

    Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03575104, the US trial registry maintained by the National Library of Medicine. NCT03575104 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.